July 29 (Reuters) - AstraZeneca's COVID-19 vaccine sales more than tripled to $894 million in the second quarter from the previous three months but shaved off 1 U.S. cent from earnings, and the drugmaker updated its 2021 forecasts on Thursday to include sales from its Alexion unit.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments